MAP2K7 and breast cancer: Notably, treatment of basal-like breast cancer cells with the MEK inhibitor PD98059 resulted in the inhibition of YBX1 function [65] and the knock-down of YBX1 in breast cancer cells harboring activated RAS resulted in growth suppression [66].